Related Experiment Video
Updated: Oct 1, 2025

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
Published on: January 29, 2014
Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients
Silvia Lucena Lage1, Joseph M Rocco1, Elizabeth Laidlaw1
1HIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States.
Insights
Complement activation on monocytes is increased in COVID-19 patients, with higher levels of C1q and C3. This monocyte-associated complement activation and CD55 upregulation persist post-infection, suggesting a role in COVID-19 pathogenesis.
Area of Science:
- Immunology
- Infectious Diseases
- Cell Biology
Background:
- Coronavirus disease-2019 (COVID-19) can lead to severe outcomes including multi-organ failure.
- Elevated complement biomarkers are linked to COVID-19 hyperinflammation and coagulopathy.
Purpose of the Study:
- To characterize systemic complement activation at the cellular level in COVID-19 patients.
- To investigate the expression of complement components and inhibitors on monocytes during COVID-19.
Main Methods:
- Flow cytometry was used to analyze complement components (C1q, C3) and inhibitors (CD55) on circulating monocytes.
- Comparison was made between 49 COVID-19 patients and healthy controls (HCs).
- Association with inflammatory markers (CRP, serum amyloid A) was assessed.
Main Results:
- COVID-19 patients showed increased C1q and C3 on monocytes compared to HCs.
- Monocytes from COVID-19 patients also exhibited upregulated cell surface-bound CD55.
- Elevated membrane-bound C1q, C3, and CD55 correlated with inflammatory markers during acute infection.
- C1q and C3 remained elevated on monocytes after a recovery period.
Conclusions:
- Systemic complement activation involving monocytes occurs broadly across COVID-19 severity.
- A compensatory upregulation of CD55 on monocytes is observed in COVID-19.
- Further research into complement-myeloid cell interactions is crucial for understanding COVID-19 pathogenesis.
Abstract:
The coronavirus disease-2019 (COVID-19) caused by the SARS-CoV-2 virus may vary from asymptomatic to severe infection with multi-organ failure and death. Increased levels of circulating complement biomarkers have been implicated in COVID-19-related hyperinflammation and coagulopathy. We characterized systemic complement activation at a cellular level in 49-patients with COVID-19. We found increases of the classical complement sentinel C1q and the downstream C3 component on circulating blood monocytes from COVID-19 patients when compared to healthy controls (HCs). Interestingly, the cell surface-bound complement inhibitor CD55 was also upregulated in COVID-19 patient monocytes in comparison with HC cells. Monocyte membrane-bound C1q, C3 and CD55 levels were associated with plasma inflammatory markers such as CRP and serum amyloid A during acute infection. Membrane-bounds C1q and C3 remained elevated even after a short recovery period. These results highlight systemic monocyte-associated complement activation over a broad range of COVID-19 disease severities, with a compensatory upregulation of CD55. Further evaluation of complement and its interaction with myeloid cells at the membrane level could improve understanding of its role in COVID-19 pathogenesis.
More Related Videos
Related Concept Videos
Complement System
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Humoral Immune Responses
Differentiation of Common Myeloid Progenitor Cells
Structure and Function of Leukocytes
White blood cells protect the body...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...

